• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

口服抗凝治疗与死亡风险:一项医疗记录关联研究。

Oral anticoagulation and risk of death: a medical record linkage study.

作者信息

Odén Anders, Fahlén Martin

机构信息

Valler 190, S-442 92 Romelanda, Sweden.

出版信息

BMJ. 2002 Nov 9;325(7372):1073-5. doi: 10.1136/bmj.325.7372.1073.

DOI:10.1136/bmj.325.7372.1073
PMID:12424167
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC131183/
Abstract

OBJECTIVE

To study how mortality varies with different degrees of anticoagulation reflected by the international normalised ratio (INR).

DESIGN

Record linkage analysis with death hazard estimated as a continuous function of INR.

DATA SOURCES

46 anticoagulation clinics in Sweden with computerised medical records.

SUBJECTS

Records for 42 451 patients, 3533 deaths, and 1.25 million INR measurements.

MAIN OUTCOME MEASURES

Mortality from all causes and from intracranial haemorrhage.

RESULTS

Mortality from all causes of death was strongly related to level of INR. Minimum risk of death was attained at 2.2 INR for all patients and 2.3 INR for patients with mechanical heart valve prostheses. A high INR was associated with an excess mortality: with an increase of 1 unit of INR above 2.5, the risks of death from cerebral bleeding (149 deaths) and from any cause were about doubled. Among patients with an INR of > or =3.0, 1069 deaths occurred within 7 weeks; if the risk coincided with that with an INR of 2.9, the expected number of deaths would have been 569. Thus at least 500 deaths were associated with a high INR value, but not necessarily caused by the treatment.

CONCLUSIONS

The excess mortality associated with high INR values supports the use of less intensive treatment and a small therapeutic window, with INR close to 2.2-2.3 irrespective of the indication for anticoagulant treatment. More preventive actions should be taken to avoid episodes of high INR.

摘要

目的

研究死亡率如何随国际标准化比值(INR)所反映的不同抗凝程度而变化。

设计

进行记录链接分析,将死亡风险估计为INR的连续函数。

数据来源

瑞典46家抗凝诊所的计算机化病历。

研究对象

42451例患者的记录、3533例死亡病例以及125万次INR测量值。

主要观察指标

全因死亡率和颅内出血死亡率。

结果

全因死亡率与INR水平密切相关。所有患者的INR为2.2时死亡风险最低,机械心脏瓣膜置换患者的INR为2.3时死亡风险最低。INR升高与死亡率增加相关:INR高于2.5每增加1个单位,脑出血(149例死亡)和全因死亡风险约增加一倍。在INR≥3.0的患者中,7周内发生了1069例死亡;如果风险与INR为2.9时一致,预期死亡人数应为569例。因此,至少500例死亡与高INR值相关,但不一定由治疗引起。

结论

与高INR值相关的额外死亡率支持采用强度较低的治疗方法和较窄的治疗窗,无论抗凝治疗指征如何,INR接近2.2 - 2.3。应采取更多预防措施以避免出现高INR情况。

相似文献

1
Oral anticoagulation and risk of death: a medical record linkage study.口服抗凝治疗与死亡风险:一项医疗记录关联研究。
BMJ. 2002 Nov 9;325(7372):1073-5. doi: 10.1136/bmj.325.7372.1073.
2
Bleeding complications and mortality in warfarin-treated VTE patients, dependence of INR variability and iTTR.华法林治疗的静脉血栓栓塞症(VTE)患者的出血并发症和死亡率、国际标准化比值(INR)变异性及个体治疗窗时间(iTTR)的相关性
Thromb Haemost. 2017 Jan 5;117(1):27-32. doi: 10.1160/TH16-06-0489. Epub 2016 Sep 22.
3
Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.华法林治疗的心房颤动患者的结局。
JAMA Cardiol. 2016 May 1;1(2):172-80. doi: 10.1001/jamacardio.2016.0199.
4
Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.口服抗凝治疗的出血并发症:一项起始队列前瞻性协作研究(ISCOAT)。意大利口服抗凝治疗并发症研究。
Lancet. 1996 Aug 17;348(9025):423-8. doi: 10.1016/s0140-6736(96)01109-9.
5
Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal.心房颤动患者预防卒中及死亡的最佳国际标准化比值:一项批判性评估
Thromb Res. 2006;117(5):493-9. doi: 10.1016/j.thromres.2004.11.025. Epub 2004 Dec 25.
6
Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin.口服抗凝药与抗血小板治疗对预防短暂性脑缺血发作或疑似动脉源性轻度卒中后进一步血管事件的比较
Cochrane Database Syst Rev. 2001(4):CD001342. doi: 10.1002/14651858.CD001342.
7
Relationship Between Anticoagulation Intensity and Thrombotic or Bleeding Outcomes Among Outpatients With Continuous-Flow Left Ventricular Assist Devices.持续血流左心室辅助装置门诊患者抗凝强度与血栓形成或出血结局的关系
Circ Heart Fail. 2016 May;9(5). doi: 10.1161/CIRCHEARTFAILURE.115.002680.
8
Questionable reversal of anticoagulation in the therapeutic management of cerebral haemorrhage associated with vitamin K antagonists.维生素 K 拮抗剂相关性脑出血治疗中抗凝作用的可疑逆转。
Thromb Haemost. 2013 Dec;110(6):1145-51. doi: 10.1160/TH13-04-0318. Epub 2013 Sep 12.
9
Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population.非瓣膜性心房颤动患者华法林治疗模式、抗凝控制水平及治疗结果的评估:一项对英国大量人群的记录链接研究
Heart. 2005 Apr;91(4):472-7. doi: 10.1136/hrt.2004.042465.
10
[Major closed-space bleeding in patients on anticoagulation with acenocoumarol (TAO) or non-fractionned heparin(HS): a case-control study].[接受醋硝香豆素(TAO)或普通肝素(HS)抗凝治疗患者的严重闭合性空间出血:一项病例对照研究]
An Med Interna. 2008 Jan;25(1):9-14. doi: 10.4321/s0212-71992008000100003.

引用本文的文献

1
Characteristics and Efficacy of Warfarin Sodium Tablet Subdivided by 3D Printing Technology: A Retrospective Cohort Study of Patients After Prosthetic Valve Replacement.3D打印技术细分华法林钠片的特征与疗效:人工瓣膜置换术后患者的回顾性队列研究
Drug Des Devel Ther. 2025 Jul 16;19:6089-6109. doi: 10.2147/DDDT.S525232. eCollection 2025.
2
Correction of Warfarin Coagulopathy for Non-bleeding Patients in the Outpatient Setting at an Ambulatory Care Organization: Application of Vitamin K Guidance.门诊护理机构非出血患者华法林凝血病的纠正:维生素K指导的应用
Cardiovasc Hematol Agents Med Chem. 2025;23(1):58-68. doi: 10.2174/0118715257286369240527055010.
3
Potential Drug-Nutrient Interactions of 45 Vitamins, Minerals, Trace Elements, and Associated Dietary Compounds with Acetylsalicylic Acid and Warfarin-A Review of the Literature.45 种维生素、矿物质、微量元素及相关膳食化合物与乙酰水杨酸和华法林的潜在药物-营养素相互作用:文献综述。
Nutrients. 2024 Mar 26;16(7):950. doi: 10.3390/nu16070950.
4
Diagnostic Performance of a Contrast-Enhanced Ultra-Low-Dose High-Pitch CT Protocol with Reduced Scan Range for Detection of Pulmonary Embolisms.一种用于检测肺栓塞的对比增强超低剂量高螺距CT协议(扫描范围缩小)的诊断性能。
Diagnostics (Basel). 2021 Jul 13;11(7):1251. doi: 10.3390/diagnostics11071251.
5
Stroke and Bleeding Risk Assessments in Patients With Atrial Fibrillation: Concepts and Controversies.心房颤动患者的卒中与出血风险评估:概念与争议
Front Med (Lausanne). 2020 Feb 21;7:54. doi: 10.3389/fmed.2020.00054. eCollection 2020.
6
Letter to the Editor: A follow-up to 'The ability of triggers to predict potentially preventable adverse events in a sample of deceased patients'.致编辑的信:对“触发因素预测已故患者样本中潜在可预防不良事件的能力”的后续跟进。
Prev Med Rep. 2019 Jun 16;15:100920. doi: 10.1016/j.pmedr.2019.100920. eCollection 2019 Sep.
7
Characteristics of patients with thromboembolic disorders on warfarin therapy in resource limited settings.资源有限环境下接受华法林治疗的血栓栓塞性疾病患者的特征
BMC Health Serv Res. 2018 Sep 19;18(1):723. doi: 10.1186/s12913-018-3537-4.
8
Impact of warfarin discharge education program on hospital readmission and treatment costs.华法林出院教育计划对医院再入院率和治疗费用的影响。
Int J Clin Pharm. 2018 Jun;40(3):721-729. doi: 10.1007/s11096-018-0631-y. Epub 2018 Mar 31.
9
Incidence and predictors of excessive warfarin anticoagulation in patients with atrial fibrillation-The EWA study.心房颤动患者华法林过度抗凝的发生率及预测因素——EWA研究
PLoS One. 2017 Apr 20;12(4):e0175975. doi: 10.1371/journal.pone.0175975. eCollection 2017.
10
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.临床药物基因组学实施联盟(CPIC)华法林给药的药物基因组学指导原则:2017年更新版
Clin Pharmacol Ther. 2017 Sep;102(3):397-404. doi: 10.1002/cpt.668. Epub 2017 Apr 4.

本文引用的文献

1
Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves.机械和生物人工心脏瓣膜患者的抗栓治疗。
Chest. 2001 Jan;119(1 Suppl):220S-227S. doi: 10.1378/chest.119.1_suppl.220s.
2
Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation.华法林抗凝过度的门诊患者结局的前瞻性研究。
Arch Intern Med. 2000 Jun 12;160(11):1612-7. doi: 10.1001/archinte.160.11.1612.
3
INR elevation associated with diarrhea in a patient receiving warfarin.一名接受华法林治疗的患者出现与腹泻相关的国际标准化比值(INR)升高。
Ann Pharmacother. 1999 Mar;33(3):301-4. doi: 10.1345/aph.18171.
4
Anticoagulation is unnecessary after biological aortic valve replacement.生物主动脉瓣置换术后无需抗凝。
Circulation. 1998 Nov 10;98(19 Suppl):II95-8; discussion II98-9.
5
Mitral valve replacement with St. Jude Medical prosthesis and low-dose anticoagulation in patients aged over 50 years.50岁以上患者使用圣犹达医疗公司人工瓣膜进行二尖瓣置换及低剂量抗凝治疗。
J Heart Valve Dis. 1998 Jul;7(4):455-9.
6
Aortic valve replacement with the St. Jude Medical prosthesis and fixed dose anticoagulation.采用圣犹达医疗公司的人工瓣膜进行主动脉瓣置换术及固定剂量抗凝治疗。
J Card Surg. 1997 Nov-Dec;12(6):363-70; discussion 371. doi: 10.1111/j.1540-8191.1997.tb00152.x.
7
High concentration of thrombomodulin in plasma is associated with hemorrhage: a prospective study in patients receiving long-term anticoagulant treatment.血浆中高浓度的血栓调节蛋白与出血相关:一项针对接受长期抗凝治疗患者的前瞻性研究。
Circulation. 1997 Nov 4;96(9):2938-43. doi: 10.1161/01.cir.96.9.2938.
8
Vulnerability to warfarin: could undernutrition be a predictor?对华法林的易感性:营养不良会是一个预测指标吗?
Arch Intern Med. 1997 Jun 23;157(12):1385.
9
Effect of different oral anticoagulant intensities on prothrombin fragment 1 + 2 in Thai patients with mechanical heart valve prostheses.不同口服抗凝强度对泰国机械心脏瓣膜置换患者凝血酶原片段1+2的影响。
J Med Assoc Thai. 1997 Feb;80(2):81-6.
10
Safer anticoagulant therapy after heart valve replacement. Recommendations for less intense regimens.心脏瓣膜置换术后更安全的抗凝治疗。低强度方案的建议。
Postgrad Med. 1997 Mar;101(3):85-6, 89-90, 93-4. doi: 10.3810/pgm.1997.03.182.